EA201692214A1 - Вещества, связывающие ядерные рецепторы - Google Patents
Вещества, связывающие ядерные рецепторыInfo
- Publication number
- EA201692214A1 EA201692214A1 EA201692214A EA201692214A EA201692214A1 EA 201692214 A1 EA201692214 A1 EA 201692214A1 EA 201692214 A EA201692214 A EA 201692214A EA 201692214 A EA201692214 A EA 201692214A EA 201692214 A1 EA201692214 A1 EA 201692214A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nuclear
- liver disease
- deposits
- receptor substances
- pharmaceutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Настоящее изобретение относится к применению соединения или его фармацевтически оптического изомера, фармацевтически приемлемой соли, фармацевтического продукта, N-оксида, гидрата или любой их комбинации представленного структурной формулой VIгде определения радикалов даны в формуле изобретения, для получения лекарственного средства для лечения, отсрочки возникновения, сокращения заболеваемости или снижения серьезности заболевания печени, обусловленного жировыми отложениями, у пациента, причем заболеванием печени, обусловленным жировыми отложениями, является неалкогольный стеатогепатит.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88147607P | 2007-01-22 | 2007-01-22 | |
US90775407P | 2007-04-16 | 2007-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201692214A1 true EA201692214A1 (ru) | 2017-11-30 |
Family
ID=39645049
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692214A EA201692214A1 (ru) | 2007-01-22 | 2008-01-22 | Вещества, связывающие ядерные рецепторы |
EA200970707A EA019833B1 (ru) | 2007-01-22 | 2008-01-22 | Вещества, связывающие ядерные рецепторы |
EA201400056A EA026578B1 (ru) | 2007-01-22 | 2008-01-22 | Вещества, связывающие ядерные рецепторы |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970707A EA019833B1 (ru) | 2007-01-22 | 2008-01-22 | Вещества, связывающие ядерные рецепторы |
EA201400056A EA026578B1 (ru) | 2007-01-22 | 2008-01-22 | Вещества, связывающие ядерные рецепторы |
Country Status (15)
Country | Link |
---|---|
US (1) | US9078888B2 (ru) |
EP (2) | EP2647376A1 (ru) |
JP (4) | JP5484914B2 (ru) |
KR (3) | KR101763674B1 (ru) |
CN (2) | CN101641013B (ru) |
AU (1) | AU2008209581B2 (ru) |
BR (1) | BRPI0806371A2 (ru) |
CA (1) | CA2676066C (ru) |
EA (3) | EA201692214A1 (ru) |
ES (1) | ES2475193T3 (ru) |
IL (2) | IL199996A (ru) |
IS (1) | IS8842A (ru) |
MX (1) | MX2009007831A (ru) |
NO (1) | NO20092822L (ru) |
WO (1) | WO2008091555A2 (ru) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
BRPI0806371A2 (pt) * | 2007-01-22 | 2011-09-13 | Gtx Inc | agentes ligação de receptor nuclear |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
WO2010017048A1 (en) * | 2008-08-06 | 2010-02-11 | Merck & Co., Inc. | Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers |
KR20110102468A (ko) * | 2008-12-16 | 2011-09-16 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 프탈라지논 및 관련 유사체 |
US20120071401A1 (en) * | 2009-04-10 | 2012-03-22 | Amylin Pharamaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
CN101928245A (zh) * | 2010-09-02 | 2010-12-29 | 西安交通大学 | 8-羟基或甲氧基-2-芳基-1-异喹啉酮及其合成方法和用途 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN102875466A (zh) * | 2012-04-23 | 2013-01-16 | 中国药科大学 | 异喹啉酮衍生物,其制备方法及其医药用途 |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
CN108143728A (zh) | 2012-07-13 | 2018-06-12 | Gtx公司 | 选择性雄激素受体调节剂在治疗乳癌中的用途 |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
WO2014037811A2 (en) | 2012-09-07 | 2014-03-13 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
WO2014039820A1 (en) * | 2012-09-07 | 2014-03-13 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
US20150246061A1 (en) * | 2012-10-19 | 2015-09-03 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
EP3041465B1 (en) | 2013-09-06 | 2020-11-11 | The University Of Montana | Method of reducing neuronal cell death with haloalkylamines |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9095505B2 (en) | 2013-11-08 | 2015-08-04 | Rbg Group, Ltd. | Pyrethroids for treatment of ocular movement disorders |
US20150133547A1 (en) * | 2013-11-08 | 2015-05-14 | Richard W. Hertle | Method and composition for treating glaucoma |
SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
KR102373700B1 (ko) * | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
ES2910128T3 (es) | 2014-04-04 | 2022-05-11 | Pfizer | Compuestos de heteroarilo o arilo fusionados con biciclo y su uso como inhibidores de IRAK4 |
CR20160563A (es) * | 2014-06-03 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
CR20160562A (es) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
CN105294561B (zh) * | 2015-11-27 | 2018-03-30 | 中国药科大学 | 一种异喹啉及其制备方法和应用 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP4096666A4 (en) * | 2020-01-29 | 2024-05-22 | Univ Georgetown | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, NEURODEVELOPMENTAL, MYODEGENERATIVE AND LYSOSOMAL STORAGE DISORDERS |
Family Cites Families (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2848356A (en) | 1954-08-30 | 1958-08-19 | Phillips Petroleum Co | Fungicides, their preparation and use |
CA1285951C (en) | 1985-10-28 | 1991-07-09 | Raj N. Misra | Naphthalenyl- and quinolinyl-amino substituted phenols |
US4921941A (en) | 1987-07-01 | 1990-05-01 | Schering Corporation | Orally active antiandrogens |
HU202842B (en) | 1988-01-27 | 1991-04-29 | May & Baker Ltd | Process for producing new isoquinolinone derivatives and pharmaceutical compositions containing them |
US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
US5112869A (en) | 1989-04-04 | 1992-05-12 | Sloan-Kettering Institute For Cancer Research | Substituted 1-phenylnaphthalenes |
KR920008026A (ko) | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
DK0590455T3 (da) | 1992-09-28 | 2001-01-22 | Hoechst Ag | Antiarrytmiske og cardioprotektive substiuerede 1(2H)-isoquinoliner, fremgangsmåde til deres fremstilling, lægemiddel indeh |
DE4333761A1 (de) | 1993-10-04 | 1995-04-06 | Luitpold Pharma Gmbh | Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
IT1307327B1 (it) | 1995-09-12 | 2001-10-30 | Smithkline Beecham Spa | Derivati idroisochinolinici sostituiti |
AU1730497A (en) | 1996-02-17 | 1997-09-02 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
SE9600769D0 (sv) | 1996-02-28 | 1996-02-28 | Astra Ab | Compounds useful as analgesic |
AU720466B2 (en) | 1996-12-27 | 2000-06-01 | Hoechst Marion Roussel, Inc. | N-(pyridinylamino)isoindolines and related compounds |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
AU6230098A (en) | 1997-02-27 | 1998-09-18 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
JPH10259176A (ja) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
JP4362638B2 (ja) | 1997-05-13 | 2009-11-11 | オクテイマー・インコーポレイテッド | pADPRTインヒビターを用いる炎症および炎症性疾患の処置法 |
US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
CZ200172A3 (cs) | 1998-07-06 | 2001-08-15 | Bristol-Myers Squibb Company | Bifenylsulfonamidy jako duální antagonisty receptoru angiotensinového a endothelinového receptoru |
JP2000072675A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
AU1199600A (en) | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
CA2367895A1 (en) | 1999-03-17 | 2000-09-21 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
DE60036476T2 (de) | 1999-08-03 | 2008-06-12 | Abbott Laboratories, Abbott Park | Kalium kanalaktivatoren |
AU1493401A (en) | 1999-09-30 | 2001-04-30 | Charlotte-Mecklenburg Hospital Authority | Treatment of carbon monoxide poisoning |
CO5271709A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
EP1257264B1 (en) | 2000-02-14 | 2011-09-14 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
WO2001064665A1 (en) | 2000-03-01 | 2001-09-07 | Akzo Nobel N.V. | Chroman derivatives as estrogenic compounds |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
HUP0303718A2 (hu) | 2000-08-23 | 2004-03-01 | Akzo Nobel N.V. | 10-Aril-11H-benzo[b]fluorén-származékok és analógok és alkalmazásuk gyógyszerkészítmények előállítására |
JP4854909B2 (ja) | 2000-09-20 | 2012-01-18 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリノン系カリウムチャンネル阻害剤 |
CA2321406A1 (en) | 2000-09-29 | 2002-03-29 | The Regents Of The University Of California | Restoration of perturbed barrier function by application of antiandrogens |
EP1328522A2 (en) | 2000-10-19 | 2003-07-23 | Merck & Co., Inc. | Estrogen receptor modulators |
AU2696502A (en) | 2000-11-27 | 2002-06-03 | Merck & Co Inc | Estrogen receptor modulators |
US7256201B2 (en) | 2000-12-07 | 2007-08-14 | Astrazeneca Ab | Selective estrogen receptor-β ligands |
US20070004713A1 (en) | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
EP1345914A1 (en) | 2000-12-22 | 2003-09-24 | AstraZeneca AB | Therapeutic compounds |
WO2002058639A2 (en) | 2001-01-23 | 2002-08-01 | Merck & Co., Inc. | Pyranoflavonoid compounds and their use as estrogen receptor modulators |
WO2002072561A1 (en) | 2001-01-26 | 2002-09-19 | Smithkline Beecham Corporation | Piperazinyltriazines as estrogen receptor modulators |
CZ20032321A3 (en) | 2001-02-02 | 2004-03-17 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
EP1389238A2 (en) | 2001-04-27 | 2004-02-18 | Bayer HealthCare AG | Regulation of human prostaglandin-f synthase 1-like protein |
ATE355278T1 (de) | 2001-05-08 | 2006-03-15 | Kudos Pharm Ltd | Isochinolinon derivate als parp inhibitoren |
JP2004530684A (ja) | 2001-05-10 | 2004-10-07 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体モジュレーター |
WO2002094790A1 (fr) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
CA2447884A1 (en) | 2001-05-25 | 2002-12-05 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
US20030119800A1 (en) | 2001-06-18 | 2003-06-26 | Manolagas Stavros C. | Bone anabolic compounds and methods of use |
US6852727B2 (en) | 2001-08-01 | 2005-02-08 | Merck & Co., Inc. | Benzimisazo[4,5-f]isoquinolinone derivatives |
EP1418900A4 (en) | 2001-08-13 | 2006-01-25 | Merck & Co Inc | SELECTIVE ESTROGEN RECEPTOR MODULATORS |
SE0103644D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
EP1478631A1 (en) | 2001-11-28 | 2004-11-24 | AstraZeneca AB | Therapeutic compounds |
UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
JP4452899B2 (ja) | 2001-12-13 | 2010-04-21 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
US6903238B2 (en) | 2001-12-13 | 2005-06-07 | Wyeth | Substituted indenones as estrogenic agents |
US6914074B2 (en) | 2001-12-13 | 2005-07-05 | Wyeth | Substituted phenyl naphthalenes as estrogenic agents |
TW200301107A (en) | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
US6960607B2 (en) | 2001-12-13 | 2005-11-01 | Wyeth | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents |
US6774248B2 (en) | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
US7015219B2 (en) | 2001-12-19 | 2006-03-21 | Bristol-Myers Squibb Company | 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators |
TW200408385A (en) | 2001-12-21 | 2004-06-01 | Akzo Nobel Nv | Tetrahydrobenzfluorene derivatives |
US6835745B2 (en) | 2002-01-15 | 2004-12-28 | Wyeth | Phenyl substituted thiophenes as estrogenic agents |
US6630508B1 (en) | 2002-02-11 | 2003-10-07 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor β agonists |
CA2476162A1 (en) | 2002-02-13 | 2003-08-21 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
AU2003212856A1 (en) | 2002-03-01 | 2003-09-16 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
US7381730B2 (en) * | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
DE60334202D1 (de) | 2002-04-24 | 2010-10-28 | Merck Sharp & Dohme | Modulatoren des östrogenrezeptors |
US20030220377A1 (en) | 2002-05-08 | 2003-11-27 | Richard Chesworth | Indole compounds and their use as estrogen agonists/antagonists |
WO2003103595A2 (en) | 2002-06-06 | 2003-12-18 | University Of Rochester | Androgen receptor coregulators |
DE10230381A1 (de) | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen |
WO2004006906A2 (en) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
US6893191B2 (en) | 2002-07-19 | 2005-05-17 | Creative Pultrusions, Inc. | Wale and retaining wall system |
AU2003255149A1 (en) | 2002-07-24 | 2004-02-09 | Kyorin Pharmaceutical Co., Ltd. | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
JPWO2004024694A1 (ja) | 2002-09-10 | 2006-01-05 | 杏林製薬株式会社 | 4−置換アリール−5−ヒドロキシイソキノリノン誘導体 |
AU2003262059A1 (en) | 2002-09-11 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
US20060183744A1 (en) | 2002-09-19 | 2006-08-17 | Rohrer Susan P | Method for treating depression and/or anxiety |
WO2004026823A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Products Inc. | Amide and sulfonamide ligands for the estrogen receptor |
AU2003287076C1 (en) * | 2002-10-15 | 2010-03-04 | University Of Tennessee Research Foundation | Heterocyclic selective androgen receptor modulators and methods of use thereof |
JP4567460B2 (ja) | 2002-11-22 | 2010-10-20 | 田辺三菱製薬株式会社 | イソキノリン化合物及びその医薬用途 |
DE60335911D1 (de) | 2002-12-20 | 2011-03-10 | Daiichi Sankyo Co Ltd | Isochinolinonderivate und deren verwendung als medikamente |
CA2512049A1 (en) | 2002-12-30 | 2004-07-22 | Purdue Research Foundation | Method of treatment for central nervous system injury |
WO2004073612A2 (en) | 2003-02-13 | 2004-09-02 | Merck & Co. Inc. | Estrogen receptor modulators |
EP1604983A4 (en) | 2003-03-17 | 2008-06-25 | Takeda Pharmaceutical | Receptor Antagonists |
US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
DK1626974T3 (da) | 2003-04-21 | 2008-11-17 | Lilly Co Eli | Substituerede benzopyraner som selektive östrogenreceptor-beta-agonister |
EP1618102B1 (en) | 2003-04-21 | 2010-02-10 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
CL2004000985A1 (es) | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
EP1633699B1 (en) | 2003-05-16 | 2007-01-03 | Wyeth | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents |
US7250440B2 (en) | 2003-08-12 | 2007-07-31 | Wyeth | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents |
JP4717815B2 (ja) | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリノンカリウムチャネル阻害剤 |
CN1856473A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉酮钾通道抑制剂 |
CA2539814C (en) | 2003-09-23 | 2010-07-06 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
ATE534404T1 (de) | 2003-10-03 | 2011-12-15 | Takeda Pharmaceutical | Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe |
EP1667989A4 (en) | 2003-10-03 | 2008-08-20 | Portola Pharm Inc | SUBSTITUTED ISOQUINOLEINONES |
US20070099880A1 (en) | 2003-11-24 | 2007-05-03 | Blizzard Timothy A | Estrogen receptor modulators |
JP2007512361A (ja) | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
WO2005051401A2 (en) | 2003-11-26 | 2005-06-09 | Schering Aktiengesellschaft | Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol |
EP1717230B1 (en) | 2004-02-13 | 2014-08-06 | Msd K.K. | Fused-ring 4-oxopyrimidine derivative |
US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
WO2005099700A1 (en) | 2004-04-06 | 2005-10-27 | Merck & Co., Inc. | Methods for the treatment of hypertension |
AU2005240609A1 (en) | 2004-05-04 | 2005-11-17 | Acadia Pharmaceuticals Inc. | Compounds with activity at estrogen receptor |
CA2569152A1 (en) | 2004-06-10 | 2005-12-29 | Merck & Co., Inc. | Estrogen receptor modulators |
EP1761270A1 (en) | 2004-06-23 | 2007-03-14 | Merck & Co., Inc. | Estrogen receptor modulators |
AU2005267210A1 (en) | 2004-06-30 | 2006-02-02 | Merck & Co., Inc. | Estrogen receptor modulators |
MXPA06015270A (es) | 2004-07-01 | 2007-03-15 | Wyeth Corp | Compuestos tetraciclicos como ligandos de estrogeno. |
DE102004039921A1 (de) | 2004-08-18 | 2006-03-02 | Henkel Kgaa | Klarspülhaltige Wasch- und Reinigungsmittel mit schwefelhaltigen Aminosäuren |
TW200621261A (en) | 2004-08-26 | 2006-07-01 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
US7354927B2 (en) | 2004-09-07 | 2008-04-08 | Wyeth | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
US7354951B2 (en) | 2004-10-18 | 2008-04-08 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
AR051597A1 (es) | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
MX2007006878A (es) | 2004-12-09 | 2007-06-22 | Merck & Co Inc | Moduladores del receptor de estrogeno. |
BRPI0519464A2 (pt) | 2004-12-31 | 2009-01-27 | Aventis Pharma Inc | uso de certos compostos fenil-naftila que nço tÊm significante afinidade para er alfa ou beta para proteÇço de neurânios e oligodendràcitos no tratamento de esclerose méltipla |
WO2006081152A2 (en) | 2005-01-24 | 2006-08-03 | Merck & Co., Inc. | Estrogen receptor modulators |
US8093302B2 (en) | 2005-02-15 | 2012-01-10 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-β agonists |
PE20061092A1 (es) | 2005-02-16 | 2006-12-05 | Wyeth Corp | COMPUESTOS HETEROCICLICOS COMO AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO |
US7482029B2 (en) | 2005-04-01 | 2009-01-27 | Bionovo, Inc. | Composition for treatment of menopause |
BRPI0608934A2 (pt) * | 2005-04-06 | 2010-02-17 | Irm Llc | compostos e composições contendo diarilamina, e seu uso como moduladores de receptores nucleares de hormÈnios esteróides |
US9763961B2 (en) | 2005-04-13 | 2017-09-19 | City Of Hope | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use |
WO2006116401A1 (en) * | 2005-04-28 | 2006-11-02 | Bristol-Myers Squibb Company | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators |
WO2007014273A2 (en) | 2005-07-25 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Sulfonamides as selective estrogen receptor modulators |
WO2007012421A1 (en) * | 2005-07-26 | 2007-02-01 | Sanofi-Aventis | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
EP1943224B1 (en) | 2005-10-05 | 2011-07-27 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
WO2007053353A2 (en) | 2005-10-28 | 2007-05-10 | Wyeth | Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
US20070197488A1 (en) | 2005-11-29 | 2007-08-23 | Olaf Peters | Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds |
EP1981539B1 (en) | 2006-02-09 | 2014-07-23 | Amgen Research (Munich) GmbH | Treatment of metastatic breast cancer |
MY149854A (en) | 2006-02-15 | 2013-10-31 | Sanofi Aventis | Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
CA2636873A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
MX2008011127A (es) | 2006-03-02 | 2008-10-31 | Astellas Pharma Inc | INHIBIDOR DE 17ß HSD TIPO 5. |
WO2007137000A2 (en) | 2006-05-16 | 2007-11-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
US20100234355A1 (en) | 2006-06-19 | 2010-09-16 | Barrie Martin | Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases |
WO2008005910A2 (en) | 2006-07-06 | 2008-01-10 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
AU2007281381A1 (en) | 2006-08-02 | 2008-02-07 | University Of Southern California | Phytoestrogenic formulations and uses thereof |
US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
BRPI0806371A2 (pt) * | 2007-01-22 | 2011-09-13 | Gtx Inc | agentes ligação de receptor nuclear |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
GB0722779D0 (en) | 2007-11-20 | 2008-01-02 | Sterix Ltd | Compound |
US20100029734A1 (en) | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
-
2008
- 2008-01-22 BR BRPI0806371-0A patent/BRPI0806371A2/pt not_active IP Right Cessation
- 2008-01-22 AU AU2008209581A patent/AU2008209581B2/en not_active Ceased
- 2008-01-22 EA EA201692214A patent/EA201692214A1/ru unknown
- 2008-01-22 CA CA2676066A patent/CA2676066C/en not_active Expired - Fee Related
- 2008-01-22 CN CN200880009379.5A patent/CN101641013B/zh not_active Expired - Fee Related
- 2008-01-22 CN CN201310311031.4A patent/CN103432133B/zh not_active Expired - Fee Related
- 2008-01-22 KR KR1020157004123A patent/KR101763674B1/ko active IP Right Grant
- 2008-01-22 ES ES08713186.8T patent/ES2475193T3/es active Active
- 2008-01-22 MX MX2009007831A patent/MX2009007831A/es active IP Right Grant
- 2008-01-22 KR KR1020097017298A patent/KR101638035B1/ko active IP Right Grant
- 2008-01-22 KR KR1020167002880A patent/KR20160020584A/ko active IP Right Grant
- 2008-01-22 EA EA200970707A patent/EA019833B1/ru not_active IP Right Cessation
- 2008-01-22 JP JP2009546440A patent/JP5484914B2/ja not_active Expired - Fee Related
- 2008-01-22 EP EP13174659.6A patent/EP2647376A1/en not_active Withdrawn
- 2008-01-22 US US12/010,225 patent/US9078888B2/en not_active Expired - Fee Related
- 2008-01-22 EP EP08713186.8A patent/EP2106212B1/en not_active Not-in-force
- 2008-01-22 EA EA201400056A patent/EA026578B1/ru not_active IP Right Cessation
- 2008-01-22 WO PCT/US2008/000736 patent/WO2008091555A2/en active Application Filing
-
2009
- 2009-07-21 IL IL199996A patent/IL199996A/en not_active IP Right Cessation
- 2009-08-11 NO NO20092822A patent/NO20092822L/no not_active Application Discontinuation
- 2009-08-11 IS IS8842A patent/IS8842A/is unknown
-
2013
- 2013-11-21 IL IL229564A patent/IL229564A/en not_active IP Right Cessation
- 2013-12-27 JP JP2013271202A patent/JP5726998B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-31 JP JP2015071973A patent/JP6122055B2/ja active Active
-
2016
- 2016-12-19 JP JP2016245320A patent/JP2017075170A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201692214A1 (ru) | Вещества, связывающие ядерные рецепторы | |
WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
PH12013501341A1 (en) | Morphinan compounds | |
CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
EA201100391A1 (ru) | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы | |
MX2014015158A (es) | Derivados de piridinona y piridazinona. | |
BR122019017036B8 (pt) | compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica | |
DK2345653T3 (da) | Morphinanforbindelser | |
MX349159B (es) | Derivados deuterados de ivacaftor. | |
EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
TN2009000444A1 (en) | Combination therapy with a compound acting as a plateletadp receptor inhibitor | |
WO2013003629A3 (en) | Methods and compositions for inhibition of bone resorption | |
ATE517882T1 (de) | Chinolinderivate | |
MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
EA200870423A1 (ru) | Производные триазолпиразинов, применимые в качестве противораковых агентов | |
ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
IN2014DN05869A (ru) | ||
WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain |